What Researchers Did
The researchers looked back at hospital records from a large United States database to compare patients with a severe soft tissue infection who received hyperbaric oxygen therapy with those who did not.
What They Found
In this retrospective study of 45,913 patients with necrotising soft tissue infection, the 405 patients who received hyperbaric oxygen therapy had lower in-hospital mortality than the others, 4.5 percent versus 9.4 percent (p equals 0.001). After adjusting for predictors and confounders, the odds ratio for dying was 0.49 (95 percent confidence interval 0.29 to 0.83). Hospitalisation cost was higher with hyperbaric oxygen, US$52,205 versus US$45,464 (p equals 0.02). Length of stay was also longer, 14.3 days versus 10.7 days (p less than 0.001). The disease itself carries a significant risk of death and long-term disability from limb and tissue loss.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
This was a retrospective analysis of a database, so the groups were not randomly assigned, and only 405 of the 45,913 patients received hyperbaric oxygen, which means other differences between the groups could account for part of the result.